Asset profile
Dostarlimab
Monoclonal antibody
Approvedregulatory verdict
Evidence outlook
Approved: JEMPERLI is a programmed death receptor-1 (PD-1)–blocking antibody indicated: Endometrial... (FDA)
This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Weak signal
Featured evidence outside covered markets:FIRST (NCT03602859) · Ovarian Neoplasms · Phase 3 · ungradedRUBY (NCT03981796) · Neoplasms · Phase 3 · ungradedNCT05855200 · Colonic Neoplasms · Phase 3 · ungraded
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
83 competitors in this universe: 22 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 61 further along in development.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Dostarlimab: this drug | Phase 3 | Monoclonal antibody | PD-1 | ||
| Cemiplimab | Approved | Monoclonal antibody | PD-1 | ||
| Nivolumab | Approved | Monoclonal antibody | PD-1 | ||
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | ||
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | ||
| Pembrolizumab Berahyaluronidase Alfa | Approved | Monoclonal antibody | PD-1 | ||
| Retifanlimab | Approved | Monoclonal antibody | PD-1 | ||
| Toripalimab | Approved | Monoclonal antibody | PD-1 | ||
| Abp 234 | Phase 3 | Monoclonal antibody | PD-1 | ||
| Balstilimab | Phase 3 | Monoclonal antibody | PD-1 | ||
| Camrelizumab | Phase 3 | Monoclonal antibody | PD-1 | ||
| Cetrelimab | Phase 3 | Monoclonal antibody | PD-1 | ||
| CT-P51 | Phase 3 | Small molecule | PD-1 | ||
| Enlonstobart | Phase 3 | Monoclonal antibody | PD-1 | ||
| MB12 | Phase 3 | Monoclonal antibody | PD-1 | ||
| Penpulimab | Phase 3 | Monoclonal antibody | PD-1 |
…and 68 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
vs Cemiplimab · Non-Small Cell Lung Cancervs Nivolumab · Non-Small Cell Lung Cancervs Pembrolizumab · Non-Small Cell Lung Cancervs Retifanlimab · Non-Small Cell Lung Cancervs Toripalimab · Non-Small Cell Lung Cancervs Camrelizumab · Non-Small Cell Lung Cancer
16 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(48 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (10)
October 2026 (1)
Phase 1/2Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM), Diffuse Intrinsic Pontine Glioma (DIPG), Ependymoma …Active not recruiting
Est. primary completion 2026-10-13 · NCT06521567 · CT.gov ↗
What to watch
November 2026 (6)
Phase 2Penile CarcinomaRecruiting
Est. primary completion 2026-11 · NCT05526989 · CT.gov ↗
What to watch
Phase 2Neoplasms, RectalActive not recruiting
Est. primary completion 2026-11-02 · NCT05723562 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-11-09 · NCT05565378 · CT.gov ↗
What to watch
Phase 2Neoplasms, ColonRecruiting
Est. primary completion 2026-11-23 · NCT06567782 · CT.gov ↗
What to watch
Phase 3NeoplasmsActive not recruiting
Est. primary completion 2026-11-26 · NCT03981796 · CT.gov ↗
What to watch
Phase 2Rectal Adenocarcinoma, Clinical Stage: Stage II (T3-4, N-), Stage III (Any T, N+), Solid Tumor, Solid Tumor, AdultRecruiting
Est. primary completion 2026-11-30 · NCT04165772 · CT.gov ↗
What to watch
December 2026 (3)
Phase 2Recurrent Cervix Cancer, Progressive Cervix CancerActive not recruiting
Est. primary completion 2026-12 · NCT04068753 · CT.gov ↗
What to watch
Phase 2Cervical Cancer, Advanced Cervical Carcinoma, Metastatic Cervical Cancer, Metastatic Cervical Carcinoma, Recurrent Cervical CarcinomaActive not recruiting
Est. primary completion 2026-12-01 · NCT06238635 · CT.gov ↗
What to watch
Phase 1NeoplasmsActive not recruiting
Est. primary completion 2026-12-31 · NCT04446351 · CT.gov ↗
What to watch
2027 (17)
January 2027 (2)
February 2027 (2)
March 2027 (4)
Phase 1/2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-03 · NCT05784012 · CT.gov ↗
What to watch
Phase 1NeoplasmsActive not recruiting
Est. primary completion 2027-03-01 · NCT02817633 · CT.gov ↗
What to watch
Phase 1Endometrial CancerRecruiting
Est. primary completion 2027-03-01 · NCT05819892 · CT.gov ↗
What to watch
Phase 1Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin NeoplasmActive not recruiting
Est. primary completion 2027-03-31 · NCT04387084 · CT.gov ↗
What to watch
April 2027 (2)
Phase 1/2Gynecologic Cancer, Carcinoma, Uterine Cancer, Endometrial CancerRecruiting
Est. primary completion 2027-04 · NCT05559879 · CT.gov ↗
What to watch
Phase 2Lung Small Cell Carcinoma, Neuroendocrine Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8 …Active not recruiting
Est. primary completion 2027-04-30 · NCT04701307 · CT.gov ↗
What to watch
June 2027 (2)
August 2027 (2)
Phase 1NeoplasmsActive not recruiting
Est. primary completion 2027-08-31 · NCT05277051 · CT.gov ↗
What to watch
Phase 2Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Vulvar Cancer, Vagina Neoplasm, Clear Cell CarcinomaRecruiting
Est. primary completion 2027-08-31 · NCT06023862 · CT.gov ↗
What to watch
October 2027 (2)
December 2027 (1)
Phase 2Colon Cancer Stage IIIRecruiting
Est. primary completion 2027-12 · NCT06830239 · CT.gov ↗
What to watch
2028 (10)
February 2028 (1)
Phase 2Pancreas NeoplasmsRecruiting
Est. primary completion 2028-02-18 · NCT06757244 · CT.gov ↗
What to watch
June 2028 (3)
Phase 2Colon Cancer, dMMR Colorectal CancerRecruiting
Est. primary completion 2028-06-30 · NCT05239546 · CT.gov ↗
What to watch
Phase 3Neoplasms, Head and NeckRecruiting
Est. primary completion 2028-06-30 · NCT06256588 · CT.gov ↗
What to watch
July 2028 (3)
Phase 2Locally Advanced Rectal Cancer (LARC)Not yet recruiting
Est. primary completion 2028-07-01 · NCT07381777 · CT.gov ↗
What to watch
Phase 2Recurrent Cancer, Primary Cancer, Second CancerRecruiting
Est. primary completion 2028-07-26 · NCT05855811 · CT.gov ↗
What to watch
Phase 2Cervical Cancer, Advanced CancerActive not recruiting
Est. primary completion 2028-07-31 · NCT03833479 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Adenocarcinoma - GEJ, Gastric AdenocarcinomaRecruiting
Est. primary completion 2028-09-01 · NCT06059495 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma, Soft Tissue Sarcoma …Recruiting
Est. primary completion 2028-10 · NCT06333314 · CT.gov ↗
What to watch
2029 (5)
March 2029 (2)
July 2029 (1)
Phase 3Neoplasms, EndometrialNot yet recruiting
Est. primary completion 2029-07-23 · NCT07684599 · CT.gov ↗
What to watch
2030 (6)
March 2030 (1)
Phase 2Neoplasms, EndometrialRecruiting
Est. primary completion 2030-03-31 · NCT07108270 · CT.gov ↗
What to watch
April 2030 (1)
Phase 2Endometrial CancerNot yet recruiting
Est. primary completion 2030-04-30 · NCT07115927 · CT.gov ↗
What to watch
June 2030 (1)
Phase 2Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2030-06-30 · NCT07408063 · CT.gov ↗
What to watch
August 2030 (1)
Phase 4Neoplasms, EndometrialNot yet recruiting
Est. primary completion 2030-08-30 · NCT07652515 · CT.gov ↗
What to watch
September 2030 (1)
Phase 3Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)Recruiting
Est. primary completion 2030-09 · NCT06762405 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer …Recruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.